At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
Public ClinicalTrials.gov record NCT04270942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatment within one year of diagnosis of clinical type 1 diabetes.
Study identification
- NCT ID
- NCT04270942
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 6 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2020 (Actual)
- Primary completion
- Jan 22, 2024 (Actual)
- Completion
- Jan 22, 2024 (Actual)
- Last update posted
- Feb 12, 2025
2020 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barbara Davis Center for Diabetes Site Number : 04 | Aurora | Colorado | 80045 | — |
| Clinical Site | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine Site Number : 01 | New Haven | Connecticut | 06511 | — |
| Clinical Site | New Haven | Connecticut | 06519 | — |
| Clinical Site | Gainesville | Florida | 32610 | — |
| University of Florida Site Number : 02 | Gainesville | Florida | 32610 | — |
| Clinical Site | Nashville | Tennessee | 37232 | — |
| Vanderbilt Univerity Medical Center Site Number : 03 | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04270942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04270942 live on ClinicalTrials.gov.